30/03/2015 10:15:22 Free Membership Login

Nymox Pharmaceutical News (NASDAQ:NYMX)

DateTimeSource
Headline
03/20/201510:34AMGLOBENymox Announces Private Placements of US$400,000
HASBROUCK HEIGHTS, N.J., March 20, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today recent private placements of 883,058 shares, with total proceeds of US$400,000. An additional 441,529 warrants exercisable at $2.00 were included in the private placements. For more information please... More...>>
01/20/20152:56PMBWUPDATE – UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corp. & I...
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014... More...>>
01/19/201510:00PMGLOBENYMOX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess ...
NEW ORLEANS, Jan. 19, 2015 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 26, 2015 to file lead plaintiff applications in a securities class action lawsuit against Nymox Pharmaceutical... More...>>
01/12/20155:33PMGLOBEUPDATE -- UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporatio...
NEW YORK, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (Nasdaq:NYMX) securities between January... More...>>
01/12/20153:09PMGLOBERosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important January 26, 2015 Class Action Deadline -- NYMX...
NEW YORK, Jan. 12, 2015 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action. To join the Nymox class action... More...>>
01/02/201512:53PMPRNUSSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its ...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX PR Newswire NEW YORK, Jan. 2, 2015 NEW YORK, Jan. 2, 2015 /PRNewswire/ -- Levi & Korsinsky announces that a class... More...>>
12/30/20148:00PMBWSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceu...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq: NYMX) common... More...>>
12/29/20144:31PMBWSHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corp. & Its Board of...
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014... More...>>
12/22/20148:18PMGLOBESHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Nymox Pharmaceu...
STEVENSON, Md., Dec. 22, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox... More...>>
12/18/201412:00PMGLOBENymox Announces $1.07 Million Financing
HASBROUCK HEIGHTS, N.J., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53. The proceeds will be used as additional funding for the Company's activities... More...>>
12/12/20144:04PMGLOBEEQUITY ALERT: Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important Class Action Deadline -- NYMX
NEW YORK, Dec. 12, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action. To join the Nymox class action... More...>>
12/11/20143:09PMGLOBESHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its ...
NEW YORK, Dec. 11, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (Nasdaq:NYMX) securities between January... More...>>
12/09/201410:00PMBWSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceu...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq: NYMX) common... More...>>
12/08/20149:11AMPRNUSLaw Offices of Marc S. Henzel Announces Securities Class Action Periods
Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire MERION, Pa., Dec. 8, 2014 MERION, Pa., Dec. 8, 2014 /PRNewswire/ -- The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following... More...>>
12/04/20141:21PMPRNUSLifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, ...
Lifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., and Spansion, Inc. PR Newswire NEW YORK, Dec. 4, 2014 NEW YORK, Dec. 4, 2014 /PRNewswire/ -- Avanir Pharmaceuticals... More...>>
11/26/20142:31PMPRNUSCohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information
Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information PR Newswire PHILADELPHIA, Nov. 26, 2014 PHILADELPHIA, Nov. 26, 2014 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating potential claims on behalf of investors who purchased Nymox... More...>>
07/22/20149:30AMGLOBENymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
HASBROUCK HEIGHTS, N.J., July 22, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce new positive efficacy data for U.S. Study NX02-0022, the Company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period... More...>>
07/15/20149:30AMGLOBENymox Announces Completion of Enrollment for Second BPH Re-Injection Study
HASBROUCK HEIGHTS, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of enrollment for Study NX02-0022, the Company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate (benign prostatic... More...>>
06/17/201410:00AMGLOBENymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
HASBROUCK HEIGHTS, N.J., June 17, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report new data supporting the positive sexual functional preservation profile of NX-1207, the Company's lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic... More...>>
06/11/201410:15AMGLOBENymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
HASBROUCK HEIGHTS, N.J., June 11, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce new clinical data supporting the positive safety profile of NX-1207, the Company's lead compound in late Phase 3 testing for prostate enlargement (BPH or benign prostate hyperplasia). Recent... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nymx150330 10:15